07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Gap junction protein β1, 32kDa (GJB1; CX32; connexin-32)

Neurology INDICATION: Neuropathy Mouse studies suggest GJB1 could help treat Charcot-Marie-Tooth type 1X (CMT1X), a disease caused by GJB1 mutations. In a GJB1-knockout mouse model of CMT1X, intrathecal injection of a viral vector encoding GJB1...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Drug-induced liver toxicity (DILI) Gap junction protein b1, 32 kDa (GJB1; CX32; connexin-32) Mouse studies identified a small molecule inhibitor of CX32 that could...
08:00 , Feb 2, 2012 |  BC Innovations  |  Targets & Mechanisms

Closing the gap on liver toxicity

U.S. researchers have identified a small molecule gap junction inhibitor that protects mice from drug-induced liver toxicity. 1 The team has founded Heprotech Inc. to further characterize and optimize the inhibitor. Gap junctions are multiprotein...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...